BioCryst Pharmaceuticals, Inc.
BCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeBioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company carries a $2.32B market cap, placing it firmly in the mid-cap category. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Market Cap
$2.32B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
9.64
EPS (TTM)
$-1.40
EPS (Fwd)
$0.94
ROE
—
ROA
52.9%
Cash
$352.6M
Total Debt
$836.6M
Free CF
$323.7M
52W Change
24.3%
Annual Financials
Cash vs Debt
Where BCRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BCRX finished 13.38% above its 150-day moving average ($8.97) and 19.09% above its 200-day moving average ($8.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCRX overbought or oversold?
At the September 3, 2026 close, BCRX's RSI(14) was 57.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BioCryst Pharmaceuticals, Inc. carries $836.6M in total debt against $352.6M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $323.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 52.9% further supports the picture of efficient asset utilization. Revenue has grown from $270.8M (2022) to $874.8M (2025), reflecting a 223% increase over the period.
The relatively low beta of 0.56 suggests BCRX is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioCryst Pharmaceuticals, Inc. and its sector.